PLK1 Downregulation Attenuates ET-1-Induced Cardiomyocyte Hypertrophy by Suppressing the ERK1/2 Pathway
Journal of Cardiovascular Translational Research · 2025
DOI: 10.1007/s12265-025-10604-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Translational Research, 2025. Verfasst von Jie Ding und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Cardiomegaly, Endothelin-1, Protein Serine-Threonine Kinases. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Shanghai Municipal Education Commission, China Postdoctoral Science Foundation, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Cardiomyocyte hypertrophy is a key remodeling response to cardiac stress and an independent risk factor for heart failure. However, the molecular mechanism of cardiomyocyte hypertrophy is not yet fully understood. We here found Polo-like kinase 1 (PLK1) was crucial in regulating endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy. Notably, PLK1 expression was significantly elevated in ET-1-induced hypertrophic cardiomyocytes and pressure overload-induced hypertrophic cardiac tissue. Knocking down Plk1 reduced the cell size of hypertrophic cardiomyocytes and suppressed the expression of hypertrophic markers, including ANP, BNP and β-MHC. The PLK1 inhibitor BI2536 had similar effects on hypertrophic cardiomyocytes. Mechanistically, the ERK1/2 pathway was identified as the key downstream pathway mediating the effects of PLK1 on ET-1-induced cardiomyocyte hypertrophy. Finally, the deficiency of PLK1 attenuated the hypertrophy of hiPSC-CMs. In summary, our study revealed that PLK1 regulates ET-1-induced cardiomyocyte hypertrophy through the ERK1/2 pathway, providing insights into the pathogenesis and potential therapies for pathological cardiac hypertrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
- Jinzhou Medical University, Jinzhou, 121000, China.
- Jinzhou Medical University, Jinzhou, 121000, China. liuyuanyuan201310@163.com.
- Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China. wuyahan_qirmai@163.com.
ORCID-Profile: Yahan Wu
Förderung
- Shanghai Municipal Education Commission
- China Postdoctoral Science Foundation
- Science and Technology Commission of Shanghai Municipality
- Shanghai Pudong New Area Health Commission
Zitieren
APA
Ding, J., Yang, A., Zhou, L., Zhang, F., Zhou, H., Zhang, Y., Wang, Y., Liu, Y., Liang, D., Liu, Y., & Wu, Y. (2025). PLK1 Downregulation Attenuates ET-1-Induced Cardiomyocyte Hypertrophy by Suppressing the ERK1/2 Pathway. Journal of Cardiovascular Translational Research. https://doi.org/10.1007/s12265-025-10604-3
Vancouver
Ding J, Yang A, Zhou L, Zhang F, Zhou H, Zhang Y, et al. PLK1 Downregulation Attenuates ET-1-Induced Cardiomyocyte Hypertrophy by Suppressing the ERK1/2 Pathway. Journal of Cardiovascular Translational Research. 2025. doi:10.1007/s12265-025-10604-3
BibTeX
@article{Ding2025,
author = {Ding, Jie and Yang, Anqi and Zhou, Liping and Zhang, Fulei and Zhou, Huixing and Zhang, Yuemei and Wang, Yan and Liu, Yi and Liang, Dandan and Liu, Yuanyuan and Wu, Yahan},
title = {PLK1 Downregulation Attenuates ET-1-Induced Cardiomyocyte Hypertrophy by Suppressing the ERK1/2 Pathway},
journal = {Journal of Cardiovascular Translational Research},
year = {2025},
doi = {10.1007/s12265-025-10604-3}
}
EUVIMED